



Prostate Cancer
Foundation
Curing Together.

2017
COFFEY-HOLDEN
PROSTATE CANCER
ACADEMY

*2017 Coffey-Holden
Prostate Cancer Academy Meeting*

**Beyond the Androgen Receptor II:
New Approaches to Understanding and
Treating Metastatic Prostate Cancer**

*June 14 - 17, 2017
Omni La Costa Resort
Carlsbad, CA*

Program Organizing Committee:

Heather Cheng, MD, PhD, Chair (University of Washington)
Wassim Abida, MD, PhD (Memorial Sloan Kettering Cancer Center)
Leigh Ellis, PhD (Dana Farber Cancer Institute)
Lauren Harshman, MD (Harvard: Dana-Farber Cancer Institute)
Christopher Kloss, PhD (University of Pennsylvania)
Daniel Spratt, MD (University of Michigan)
Howard Soule, PhD (Prostate Cancer Foundation)
Kenneth Pienta, MD (Johns Hopkins University)
Andrea Miyahira, PhD (Prostate Cancer Foundation)



WEDNESDAY, JUNE 14, 2017

3:00 PM - 5:00 PM	Registration	<i>Veranda Foyer</i>
5:00 PM - 6:00 PM	Welcome Reception	<i>Legends Lawn</i>
6:00 PM - 7:15 PM	Welcome Dinner	<i>Parlor</i>
7:15 PM - 7:30 PM	Move to Session I	<i>Veranda</i>

Session I: Introduction

Location: *Veranda*

7:30 PM - 7:40 PM	Welcome and Opening Remarks Howard Soule, PhD Prostate Cancer Foundation
-------------------	--

Distinguished Lecture:

7:40 PM - 8:10 PM

**“Learning from the Astronomers—
How Astronomy Can Inform Cancer Immunotherapy Investigation”**

Alex Szalay, PhD

Johns Hopkins School of Medicine

Discussion

8:10 PM - 8:30 PM

First Question: Robert Den, MD

8:30 PM - 9:15 PM	AFFINITY GROUPS I
-------------------	--------------------------



THURSDAY, JUNE 15, 2017

6:15 AM	Registration	<i>Veranda Foyer</i>
6:15 AM - 7:15 AM	Breakfast	<i>Legends Lawn</i>
7:15 AM - 7:30 AM	Move to Session II	<i>Veranda</i>

Session II: Charge to Participants: The Big Questions

7:30 AM - 8:00 AM	The Big Questions Kenneth Pienta, MD Johns Hopkins University
-------------------	---

Session III: Histologic Transformation: When AR disappears

Session Chair:	Leigh Ellis, PhD Harvard: Dana-Farber Cancer Institute
8:00 AM - 8:10 AM	Towards Defining Molecular Subclasses of Treatment Resistant Prostate Cancer Himisha Beltran, MD Weill Cornell Medicine
8:10 AM - 8:30 AM	Discussion First Question: Colin Pritchard, MD, PhD
8:30 AM - 8:40 AM	Targeting the 'Identity Fraud' In Prostate Cancer Ping Mu, PhD Memorial Sloan Kettering Cancer Center
8:40 AM - 9:00 AM	Discussion First Question: Tamara Lotan, MD
9:00 AM - 9:10 AM	Therapeutic Vulnerabilities Arising From Neuroendocrine Transdifferentiation of Prostate Cancer John K. Lee, MD, PhD University of California, Los Angeles
9:10 AM - 9:30 AM	Discussion First Question: William Nelson, MD, PhD
9:30 AM - 9:45 AM	Break



Thursday, June 15, 2017

- 9:45 AM - 9:55 AM **Patient-derived tumor organoids of neuroendocrine prostate cancer to explore novel therapeutic strategies**
Loredana Puca, PhD
Weill Cornell Medicine
- 9:55 AM - 10:15 AM Discussion
First Question: Daniel Spratt, MD
- 10:15 AM - 10:25 AM **The Role of N-Myc in Driving Lineage Plasticity**
David Rickman, PhD
Weill Cornell Medicine
- 10:25 AM - 10:45 AM Discussion
First Question: Rana McKay, MD

Session IVa: Epigenetic Regulation and Targeting

Session Chair: **Wassim Abida, MD, PhD**
Memorial Sloan Kettering Cancer Center

Distinguished Lecture:

10:45 AM - 11:05 AM
Context-Dependent Glucocorticoid Receptor Activity in Prostate (and Breast) Cancer
Suzanne Conzen, MD
University of Chicago

Discussion
11:05 AM - 11:25 AM
First Question: Joshua Lang, MD

- 11:30 AM - 12:45 PM **Lunch** *Legends Lawn*
- 12:45 PM - 1:00 PM **Move to Session IVb**



Thursday, June 15, 2017

Session IVb: Epigenetic Regulation and Targeting

Session Chair: **Wassim Abida, MD, PhD**
Memorial Sloan Kettering Cancer Center

1:00 PM - 1:10 PM **Tumor glucocorticoid metabolism enables enzalutamide-resistant prostate cancer**

Nima Sharifi, MD
The Cleveland Clinic

1:10 PM - 1:30 PM Discussion
First Question: Christina Jamieson, PhD

1:30 PM - 1:40 PM **Charting the epigenetic landscape of the androgen receptor**

Mark Pomerantz, MD
Harvard: Dana-Farber Cancer Institute

1:40 PM - 2:00 PM Discussion
First Question: Ravi Madan, MD

2:00 PM - 2:10 PM **Epigenetic regulation of the glucocorticoid receptor drives drug resistance in prostate cancer**

Neel Shah
Memorial Sloan Kettering Cancer Center

2:10 PM - 2:30 PM Discussion
First Question: Joshi Alumkal, MD

2:30 PM - 2:45 PM **Break**

Session V: DNA Repair

Session Chair: **Heather Cheng, MD, PhD**
University of Washington

Distinguished Lecture:

2:45 PM - 3:05 PM

Biomarkers of DNA Repair Deficiency

Elizabeth Swisher, MD
University of Washington

Discussion

3:05 PM - 3:25 PM

First Question: Mark Markowski, MD, PhD



Thursday, June 15, 2017

- | | |
|-------------------|--|
| 3:25 PM - 3:35 PM | Cotargeting PARP Inhibition
Reem Malek, PhD
Johns Hopkins University |
| 3:35 PM - 3:55 PM | Discussion
First Question: Russell Pachynski, MD |
| 3:55 PM - 4:05 PM | Interplay between Androgen Receptor and PARP
Matthew Schiewer, PhD
Thomas Jefferson University |
| 4:05 PM - 4:25 PM | Discussion
First Question: Saul Priceman, PhD |
| 4:25 PM - 4:35 PM | The Role of SPOP in DNA repair
Christopher Barbieri, MD, PhD
Weill Cornell Medicine |
| 4:35 PM - 4:55 PM | Discussion
First Question: Karen Sfanos, PhD |

Session VI: Advancing the Use of Germline Genetics in Clinical Practice

Session Chair: **Heather Cheng, MD PhD**
University of Washington

Distinguished Lecture:
4:55 PM - 5:15 PM
Integrating *BRCA* Research, Care and Patient Experience
Pamela Munster, MD
University of California, San Francisco

Discussion
5:15 PM - 5:35 PM
First Question: Christopher Logothetis, MD

- | | | |
|-------------------|---------------------------|---------------------|
| 5:45 PM - 7:00 PM | Dinner | <i>Legends Lawn</i> |
| 7:00 PM - 7:15 PM | Move to Session VI | <i>Veranda</i> |



Thursday, June 15, 2017

Distinguished Lecture:

7:15 PM - 7:35 PM

Cancer Genetics: Translation and Diversification

Olufunmilayo Olopade, MD

University of Chicago

Discussion

7:35 PM - 7:55 PM

First Question: Amina Zoubeidi, PhD

7:55 PM - 8:05 PM

Patient Partnership in Genomics Research

John Gore, MD

University of Washington

8:05 PM - 8:25 PM

Discussion

First Question: Leigh Ellis, PhD

8:25 PM - 8:35 PM

Clinical Implications of Germline BRCA: Urology Perspective

Todd Morgan, MD

University of Michigan

8:35 PM - 8:55 PM

Discussion

First Question: Howard Scher, MD

8:55 PM - 9:30 PM

AFFINITY GROUPS II



FRIDAY, JUNE 16, 2017

7:00 AM - 7:45 AM	Breakfast	<i>Legends Lawn</i>
7:45 AM - 8:00 AM	Move to Session VII	<i>Veranda</i>

Session VII: Prostate Cancer Theranostics

Session Chair: **Daniel Spratt, MD**
University of Michigan

Distinguished Lecture:
8:00 AM - 8:20 AM
Overview of Radionuclides for Imaging and Therapy
Oliver Sartor, MD
Tulane Cancer Center

Discussion
8:20 AM - 8:40 AM
First Question: Haydn Kissick, PhD

8:40 AM - 8:50 AM	Small Molecules, Mini-bodies, Antibodies: Does size matter? Neil Bander, MD Weill Cornell Medicine
8:50 AM - 9:10 AM	Discussion First Question: Irfan Asangani, PhD
9:10 AM - 9:20 AM	Use of C11-Choline PET in Oligometastatic Disease Jeff Karnes, MD Mayo Clinic
9:20 AM - 9:40 AM	Discussion First Question: Lauren Harshman, MD
9:40 AM - 9:50 AM	Use of PSMA PET in Oligometastatic Disease Steven Rowe, MD, PhD Johns Hopkins University
9:50 AM - 10:10 AM	Discussion First Question: Adam Dicker, MD, PhD



Friday, June 16, 2017

10:10 AM - 10:20 AM **Diagnostic and Therapeutic uses of PSMA**
Ken Herrmann, MD
 University of California, Los Angeles

10:20 AM - 10:40 AM Discussion
 First Question: Steven Balk, MD, PhD

Distinguished Lecture:
10:40 AM - 11:00 AM
NextGen Prostate Cancer Treatments will Feature NextEpigen Approaches
William Nelson, MD, PhD
 Johns Hopkins University

Discussion
11:00 AM - 11:20 AM
 First Question: Akash Patnaik, MD, PhD

11:20 AM -11:30 AM **Group Photos**

11:30 AM - 1:15 PM **Lunch** *Legends Lawn*

Free Afternoon

1:15 PM - 2:15 PM **Personal Training Session** *Bougainvillea Courtyard*
(RSVP required, limited availability)
Lunch available immediately following training session

5:15 PM - 6:15 PM **Dinner** *Legends Lawn*

6:15 PM - 6:30 PM **Move to Session VIII** *Veranda*

Friday, June 16, 2017

Session VIII: Immunology

Session Chair: **Lauren Harshman, MD**
Harvard: Dana-Farber Cancer Institute

Distinguished Lecture:

6:30 PM - 6:50 PM

Cracking a Tough Nut: Immunotherapy for Prostate Cancer

Charles Drake, MD, PhD

Columbia University

Discussion

6:50 PM - 7:10 PM

First Question: Ana Aparicio, MD

7:10 PM - 7:20 PM

**Radium-223 as an Immunomodulator—ongoing studies with
Checkpoint Inhibition**

Ravi Madan, MD

National Cancer Institute

7:20 PM - 7:40 PM

Discussion

First Question: Andrew Armstrong, MD

7:40 PM - 7:50 PM

Priming the Immune System with GM-CSF Prior to Prostatectomy

Xiao Wei, MD

University of California, San Francisco

7:50 PM - 8:10 PM

Discussion

First Question: Glenn Liu, MD

8:10 PM - 8:20 PM

Overcoming Immune Escape with a MIC-A Vaccine

Soumya Badrinath, PhD

Harvard: Dana-Farber Cancer Institute

8:20 PM - 8:40 PM

Discussion

First Question: Heather Cheng, MD, PhD

Distinguished Lecture:

8:40 PM - 9:00 PM

From Bench to Bedside: Marrying a DNA Vaccine with Checkpoint Inhibition in PC

Douglas McNeel, MD, PhD

University of Wisconsin

Discussion

9:00 PM - 9:20 PM

First Question: William Dahut, MD

SATURDAY, JUNE 17, 2017

7:00 AM - 7:45 AM **Breakfast** *Legends Lawn*

7:45 AM - 8:00 AM **Move to Session IX** *Veranda*

Session IX: Immunotherapeutic Approaches to Prostate Cancer: To be or not to be specific

Session Chair: **Saul Priceman, PhD**
City of Hope

8:00 AM - 8:10 AM **Targeting soluble NKG2D ligands to treat metastatic prostate cancer: preclinical and clinical rationale**

Jennifer Wu, PhD
Medical University of South Carolina

8:10 AM - 8:30 AM Discussion
First Question: David Miyamoto, MD, PhD

8:30 AM - 8:40 AM **Combination immunotherapy for prostate cancer: OX40 agonists, checkpoint blockade, and beyond**

William Redmond, PhD
Providence Portland Medical Center/Earle A. Chiles Research Institute

8:40 AM – 9:00 AM Discussion
First Question: Reem Malek, PhD

9:00 AM - 9:10 AM **Inflammation-induced suppression of cytotoxic T cell activation as a tumor promoting mechanism**

Shabnam Shalapour, PhD
University of California, San Diego

9:10 AM - 9:30 AM Discussion
First Question: Massimo Loda, MD

9:30 AM - 9:40 AM **Challenges and opportunities for immunotherapy in prostate cancer**

James Gulley, MD, PhD

National Cancer Institute
Discussion
First Question: Wassim Abida, MD, PhD

10:00 AM - 10:30 AM **AFFINITY GROUPS III**



Prostate Cancer
Foundation
Curing Together.

2017
COFFEY-HOLDEN
PROSTATE CANCER
ACADEMY

Saturday, June 17, 2017

Session X: Closing Remarks

10:30 AM - 10:50 AM

Meeting Debrief

Kenneth Pienta, MD

Johns Hopkins University

Howard Soule, PhD

Prostate Cancer Foundation

Departures - *Boxed Lunches Provided*